灵康药业
(603669)
| 流通市值：40.10亿 | | | 总市值：40.10亿 |
| 流通股本：7.21亿 | | | 总股本：7.21亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 171,607,603.84 | 50,121,123.94 | 379,780,224.17 | 231,030,545.43 |
| 营业收入 | 171,607,603.84 | 50,121,123.94 | 379,780,224.17 | 231,030,545.43 |
| 二、营业总成本 | 209,257,335.21 | 62,962,253.24 | 466,355,331.15 | 269,783,181.71 |
| 营业成本 | 140,924,941.42 | 36,073,102.81 | 201,737,206.04 | 131,550,413.16 |
| 税金及附加 | 1,506,711.45 | 670,940.05 | 4,822,021.42 | 2,204,406.23 |
| 销售费用 | 15,787,866.5 | 3,959,472.65 | 141,995,468.58 | 75,164,260.53 |
| 管理费用 | 35,884,284.09 | 13,441,864.23 | 89,519,946.76 | 64,913,652.88 |
| 研发费用 | 5,029,204.5 | 3,811,891.38 | 26,664,860.9 | 14,987,666.9 |
| 财务费用 | 10,124,327.25 | 5,004,982.12 | 1,615,827.45 | -19,037,217.99 |
| 其中:利息费用 | 10,272,529.67 | 5,067,230.28 | 27,377,086.77 | 6,504,446.24 |
| 其中:利息收入 | 164,975.18 | 71,787.03 | 1,292,094.02 | 1,040,655.66 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -347,222.93 | -141,122.08 | 5,903,731.69 | 1,745,296.94 |
| 加:投资收益 | -3,046,508.71 | -3,346,482.54 | -12,723,355.72 | -11,987,579.54 |
| 资产处置收益 | -49,322.73 | -79,035.79 | -2,235,606.34 | -2,250,203.86 |
| 资产减值损失(新) | -107,822.6 | -5,099.23 | -32,296,796.18 | -46,298.03 |
| 信用减值损失(新) | -3,997,851.07 | -1,830,427.17 | -18,766,059.18 | -16,226,317.27 |
| 其他收益 | 10,331,669.39 | 394,951.48 | 17,924,604.47 | 14,520,400.49 |
| 四、营业利润 | -34,866,790.02 | -17,848,344.63 | -128,768,588.24 | -52,997,337.55 |
| 加:营业外收入 | 2,698.12 | 0.23 | 1,549,575.65 | 5,573,437.97 |
| 减:营业外支出 | 1,102,127.53 | 889,162.89 | 509,836.45 | 278,905.33 |
| 五、利润总额 | -35,966,219.43 | -18,737,507.29 | -127,728,849.04 | -47,702,804.91 |
| 减:所得税费用 | -232,533.66 | -116,266.83 | 3,034,839.81 | -812,916.68 |
| 六、净利润 | -35,733,685.77 | -18,621,240.46 | -130,763,688.85 | -46,889,888.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -35,733,685.77 | -18,621,240.46 | -130,763,688.85 | -46,889,888.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -35,733,685.77 | -18,621,240.46 | -130,763,688.85 | -46,889,888.23 |
| 扣除非经常损益后的净利润 | -45,544,900.33 | -17,914,891.38 | -180,173,693.87 | -90,862,499.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | -0.03 | -0.18 | -0.07 |
| (二)稀释每股收益 | -0.05 | -0.03 | -0.18 | -0.07 |
| 八、其他综合收益 | - | - | -2,268,192.29 | - |
| 归属于母公司股东的其他综合收益 | - | - | -2,268,192.29 | - |
| 九、综合收益总额 | -35,733,685.77 | -18,621,240.46 | -133,031,881.14 | -46,889,888.23 |
| 归属于母公司股东的综合收益总额 | -35,733,685.77 | -18,621,240.46 | -133,031,881.14 | -46,889,888.23 |
| 公告日期 | 2025-08-23 | 2025-04-26 | 2025-04-19 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |